( ated clinical benefit. Fifty-eightperc...)ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference,Health

ated clinical benefit. Fifty-eight percent of patients in the Traficet-EN group experienced a 70 point or greater drop in CDAI scores compared to 31 percent of those who received placebo. Importantly, Traficet-EN's anti-inflammatory activity was demonstrated by a decrease in CRP levels, which serve as a systemic marker of inflammation, of 11 mg/L in the treatment group compared to placebo.

"We are very pleased to have seen clear signs of clinical activity in this four week study of Traficet-EN. Patients with active disease reported significant improvement in their condition when treated with Traficet-EN compared to those in the control group," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx, Inc. "In addition, the results from this group of patients in our Phase 2 trial are in line with the latest research from key opinion leaders. Current research has shown that CDAI scores of 250 and above, combined with elevated CRP serum levels at baseline, help to identify patients with actual Crohn's disease and may thereby reduce the high placebo response rate frequently observed in Crohn's disease clinical trials. We are currently using these parameters as enrollment criteria in our ongoing long-term clinical study, known as PROTECT-1, which

will evaluate Traficet-EN's ability to induce response or remission, as well as at the drug's potential as maintenance therapy."

The oral presentation of Phase 2 data, titled "CCX282-B, an orally active inhibitor of chemokine receptor CCR9, shows anti-inflammatory and clinical activity in the treatment of Crohn's Disease" was provided today by Dr. Keshav as part of the Advances in Crohn's Disease session. Data from the Phase 2 trial were also selected for presentation during the "Best of UEGW" session sponsored by the American Gastroenterological Association (AGA) yesterday afternoon. The Phase 2 randomized double-blind, placebo-controlled clinical trial was designed to ev
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference